United Therapeutics CORP Form 4 insider transactions

Ray Kurzweil, a director at United Therapeutics Corp, exercised stock options and subsequently sold an equal number of common shares.

United Therapeutics Director Tommy G. Thompson exercised stock options and subsequently sold an equal number of common shares for a significant profit.

United Therapeutics Director Christopher Causey exercised stock options and sold shares totaling 20 units under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, exercised stock options and sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold the resulting shares as part of a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Judy D. Olian sold 200 shares of common stock for $509.55 per share under a pre-arranged 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, was awarded performance-based stock options and restricted stock units on March 15, 2023, contingent on future company performance.

United Therapeutics CEO Martine Rothblatt has earned significant performance-based stock options and restricted stock units tied to 2023-2025 financial and clinical goals.

United Therapeutics' President and COO, Michael Benkowitz, has earned significant performance-based stock options and restricted stock units following the achievement of multi-year targets.

United Therapeutics CFO James Edgemond earned significant performance-based stock options and restricted stock units following the achievement of multi-year company targets.

Christopher Causey, a Director at United Therapeutics Corp, executed a pre-planned sale of 1,000 common shares following the exercise of stock options.

United Therapeutics' President and COO Michael Benkowitz completed the sale of 14,440 shares of common stock through a pre-arranged 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold the resulting shares under a pre-arranged 10b5-1 plan.

United Therapeutics COO Michael Benkowitz sold shares acquired through option exercises under a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 8,300 shares of common stock.

United Therapeutics Director Jan Malcolm sold 50 shares of common stock for $474.23 per share under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp's President and COO, Michael Benkowitz, exercised stock options and sold 22,500 common shares as part of a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics' President and COO, Michael Benkowitz, executed pre-planned sales of common stock totaling 30,375 shares after exercising stock options.

United Therapeutics President and COO Michael Benkowitz exercised options and sold 14,625 shares of common stock as part of a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics Director Kevin Tracey received 1,220 restricted stock units as part of his compensation, vesting on January 21, 2027.

A director at United Therapeutics Corporation sold 50 shares of common stock for $460.98 per share under a pre-arranged trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 8,300 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics' President and COO, Michael Benkowitz, completed a pre-scheduled exercise of stock options and subsequent sale of common stock.

United Therapeutics President and COO Michael Benkowitz executed a pre-arranged sale of 14,625 common shares following the exercise of stock options, as disclosed in a recent SEC Form 4 filing.

United Therapeutics President and COO Michael Benkowitz exercised stock options and sold the resulting shares totaling 7,875, pursuant to a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Christopher Causey exercised stock options and subsequently sold 1,000 shares of common stock for $510 per share under a pre-arranged 10b5-1 plan.

United Therapeutics Director Jan Malcolm sold 50 shares of common stock for $495.01 per share under a pre-arranged 10b5-1 trading plan.

Christopher Causey, a director at United Therapeutics Corp, exercised stock options and subsequently sold 1,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and sold 8,300 shares of common stock on January 2, 2026, under a pre-arranged 10b5-1 plan.

United Therapeutics Corp's President and COO, Michael Benkowitz, exercised stock options and sold the resulting shares totaling 22,500 under a pre-arranged 10b5-1 trading plan.